1. Analysis of Ibandronate Sodium Hydrate Proposed in USP-NF Pharmacopeial Forum (I-524A)
  2. Separation of Fosfomycin and its Thermal Decomposition Products (NH2P-50 4E)
  3. Separation of Ceftazidime and Arginine (KW402.5-4F)
  4. Analysis of Calcium Acetate Capsules According to USP-NF Method (YK-421)
  5. Analysis of Potassium and Sodium Bicarbonates and Citric Acid Effervescent Tablets for Oral Solution According to USP-NF Method (YK-421)
  6. Analysis of Potassium Bicarbonate and Potassium Chloride Effervescent Tablets for Oral Solution According to USP-NF Method (YK-421)
  7. Analysis of Zinc Sulfate Compounded Injection According to USP-NF Method (YK-421)
  8. Analysis of Pamidronate Disodium According to USP-NF Method (IC I-524A)
  9. Analysis of Zoledronic Acid (IC I-524A)
  10. Analysis of Ibandronate Sodium (IC I-524A)
  11. Analysis of Sodium Risedronate (IC I-524A)
  12. Analysis of Inositol According to Japanese Pharmaceutical Excipients 2018 (KS-801)
  13. SEC Analysis of Filgrastim (KW-803)
  14. Analysis of Levocarnitine (NH2P-50 4E)
  15. Analysis of Oligomers in Omega-3 Free Fatty Acids According to USP-NF (KF-802.5 + KF-802 + KF801)
  16. LC/MS Analysis of Macrolide Antibiotics (C18U 2B)
  17. Analysis of Trypsin-Digested Rituximab (C18U 2D)
  18. Analysis of Allantoin in a Commercial Disinfectant (VG-50 4E)
  19. SEC Analysis of Liraglutide Formulation (KW-802.5)
  20. SEC Analysis of PEG-Asparaginase (SB-806 HQ)
  21. Analysis of Teriparatide According to EP Method (KW-802.5)
  22. Analysis of Azithromycin Injection According to USP Method (ODP-50 4D)
  23. Quantification of Alendronate Sodium Injection According to JP Method (DS-613)
  24. Quantification of Alendronate Sodium Tablets According to JP Method (DS-613)
  25. Quantification of Alendronate Sodium Hydrate According to JP Method (DS-413)
  26. Quantification of Alendronate Sodium Hydrate and Its Related Compound According to JP Method (DS-413)
  27. Analysis of Erythropoietin According to EP Method (LW-803)
  28. SEC Analysis of Rituximab (LW-803)
  29. Analysis of Somatropin According to EP Method (LW-803)
  30. Exenatide Analysis According to USP Method (KW-802.5)
  31. Analysis of α-GPC in Supplements (NH2P-50 4E)
  32. Ginsenoside (Carrot Saponin) (NH2P-50 4E)
  33. SEC Analysis of Saccharated Ferric Oxide Injection (SB-804 HQ + SB-802.5 HQ)
  34. Impurity Analysis of Lamivudine According to USP Method (CDBS-453)
  35. Impurity Analysis of Voriconazole According to USP Method (CDBS-453)
  36. Analysis of Formoterol Fumarate Dihydrate According to Pharmacopeia Method (ODP-50 4D)
  37. LC/MS/MS Analysis of Salacia Extract (2) (VT-50 2D)
  38. LC/MS/MS Analysis of Salacia Extract (1) (VC-50 2D)
  39. LC/MS/MS Analysis of Citicoline (VT-50 2D)
  40. LC/MS Analysis of Streptomycins (VC-50 2D)
  41. Comparison of Analysis of Glucosamine Hydrochloride between Polymer-based Amino Columns and Silica-based Amino Columns
  42. Assay of Polyethylene Glycol 3350 for Oral Solution According to USP Method (SB-802.5 HQ)
  43. Measurement of Apparent Weight-Average Molecular Weight and Polydispersity of Polyethylene Glycol 3350 According to USP Method (SB-803 HQ)
  44. LC/MS/MS Analysis of Salacia Extract (1) (VC-50 2D)
  45. LC/MS/MS Analysis of Ribavirin (VC-50 2D)
  46. Analysis of High Molecular Impurities in Insulin Aspart According to Pharmacopoeia Method (KW-802.5)
  47. LC/MS Analysis of Aminoglycoside Antibiotics (VC-50 2D)
  48. Drugs (ODP-50 4D)
  49. Soyasaponin in Soy Bean (DS-613)
  50. LC/MS/MS Analysis of Oral Anti-diabetes Drugs (VC-50 2D)
  51. Analysis of Voglibose According to JP Method (NH2P-50 4E)
  52. Bibliographic Information for Analysis of Conjugate Vaccine
  53. Separation of Gingerol and Shogaol (C18M 4D)
  54. Analysis of Purified Sodium Hyaluronate Ophthalmic Solution According to JP Method (SB-802.5 HQ)
  55. Analysis of Miglitol According to JP Method NH2P-50 4E
  56. Analysis of Insulin According to USP Method (KW-802.5)
  57. Analysis of Insulin Glargine According to JP Method (KW-802.5)
  58. Analysis of Insulin Human According to JP Method (KW-802.5)
  59. Analysis of Zanamivir According to USP Method (NH2P-50 4E)
  60. Analysis of Azithromycin According to USP Method (ODP-50 4E)
  61. Simultaneous Analysis of Multi Symptom Cold Formula (ODP2 HP)
  62. Simultaneous Analysis of Multi Symptom Cold Formula in Serum (ODP2 HP)
  63. LC/MS Analysis of Statins (ODP2 HP-2B)
  64. LC/MS Analysis of Basic Drugs (ODP40-2D)
  65. Anti-diabetes drugs (NH2P-50 4E)
  66. Ribavirin (KS-801)
  67. Ginsenoside (Ginseng Saponin)
  68. Short Amines (ODP2 HP-4D)
  69. Analysis of Short Amines without Using Ion Pair Reagent
  70. Procaine and Procaineamide (ODP-50 4D)
  71. Methylxanthine (1) (DS-613)
  72. Methylxanthine (2)
  73. Local Anesthetics (1) (ODP-50 4D)
  74. Local Anesthetics (2) (DE-413)
  75. Cinchona Alkaloids
  76. Antibiotics (1) (ODP-50 4D)
  77. Antibiotics (2) (DE-413)
  78. Sulfanilamides (DE-413)
  79. Barbiturates (ODP-50 4D)
  80. Effect of pH of Eluent on Sensitivity of Barbital
  81. Berberine in Japanese Goldthread
  82. Glycyrrhizin in Licorice
  83. Saikosaponins (ODP-50 6D)
  84. Soysaponin in Soy Beans (DS-613)
  85. Curative Drugs to Eradicate H.Pyrori (JJ-50 2D)
  86. Enalapril Maleate (DS-413)
  87. Basic Drugs : Under Neutral Condition
  88. Basic Drugs : Effect of Eluent pH
  89. Basic Drugs : Effect of Ion Concentration
  90. Antifebriles (1) (DS-613)
  91. Antifebriles (2) (DM-614)
  92. Antipyretic Analgesics (ODP-50 4D)
  93. Diuretics (1) (ODP-50 4D)
  94. Diuretics (2) (DE-613)
  95. Anti Cancer Drugs (ODP-50 4D)
  96. Drugs
  97. Anti Inflammatory Drugs (1) (ODP-50 4E)
  98. Anti Inflammatory Drugs (2) (ODP-50 4E)
  99. Scopolamine and Atropine (ODP-50 4D)
  100. Tetracaine (ODP-50 4D)
  101. Effect of pH of Eluent on Elution Volume and Plate Number
  102. Procainamides (1) (DE-613)
  103. Procainamides (2) (DE-413)

Drugs in Blood and Urine:

  1. LC/MS/MS Analysis of Tricyclic Antidepressants in BSA (ODP2 HP)
  2. Analysis of Anticonvulsant in Serum (ODP2 HP)
  3. Acetaminophen in serum (ODP2 HP)
  4. Risperidone in urine (ODP2 HP)
  5. Influence of Proteins in LC/MS Analysis
  6. LC/MS Analysis of Drugs in BSA (1) (ODP2 HP)
  7. LC/MS Analysis of Drugs in BSA (2) (ODP2 HP)
  8. LC/MS Analysis of drugs in Control Serum (ODP2 HP)
  9. Reproducibility in LC/MS Analysis (ODP2 HP)
  10. Influence of Flow Rate (ODP2 HP)
  11. LC/MS Analysis of Barbital in BSA (ODP2 HP-2B)
  12. Indomethacin
  13. Procainamide in Serum
  14. Theophylline in Serum
  15. Methamphetamine in Urine

Antibody Drug Conjugates:

  1. SEC Analysis of Antibody Drug Conjugate (LW-803)

Chiral Compounds:

  1. Chiral Separation of Norepinephrine (CDBS-453)
  2. Analysis of Epinephrine According to USP (In-Process Revision) (CDBS-453)
  3. Selection of Chiral Separation Columns
  4. Chlortharidone (2)
  5. Lorazepam (CDBS-453)
  6. Bromoisovalerylurea
  7. Chlorthalidone (1)
  8. Chlorpheniramine and Metabolic Intermediates
  9. Epinephrine (CDBS-453)


  1. Analysis of Choline and Acetylcholine (YS-50)
  2. LC/MS Analysis of Choline and Acetylcholine (VC-50 2D)
  3. HVA and VMA Standards
  4. Analysis of VMA and Creatinine using Column Switching Method
  5. HVA and VMA in Urine
  6. Analysis of Uric Acid and Creatinine using Column Switching Method
  7. Hippuric Acid etc. in Urine (2)
  8. Polyamine and Acetylated Derivatives (ODP-50 4E)
  9. Instruments for On-Column Derivatization
  10. Analysis of Polyamines by On-Column Derivertization
  11. Analysis of Histamine by On-Column Derivatization
  12. Kojic Acid